Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 14:55 ET | Source: Allsup

Allsup Helps Individuals With Crohn’s Disease And Ulcerative Colitis Overcome Barriers To SSDI Benefits

Belleville, Illinois, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...
October 24, 2025 08:02 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous...
September 19, 2025 10:10 ET | Source: Janssen Cilag International NV

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and...
September 02, 2025 08:00 ET | Source: OMass Therapeutics

OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million...
September 02, 2025 03:00 ET | Source: OMass Therapeutics

OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel diseaseOMass to receive $20 million...
August 01, 2025 08:30 ET | Source: SNS Insider pvt ltd

Fecal Calprotectin Testing Market to Hit USD 12.23 Billion by 2032, Driven by Rising Prevalence of IBD and Demand for Non-Invasive Diagnostic Tools - SNS Insider

Austin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Fecal Calprotectin Testing Market Size & Trends: According to SNS Insider, the global Fecal Calprotectin Testing Market was valued at USD 4.51 billion...
June 11, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea adds ETS2 expert Dr. James Lee to its SAB to guide PAS-004 development for IBD and other inflammatory diseases driven by ETS2.
June 10, 2025 07:00 ET | Source: Quell TX

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease AstraZeneca exercises option to license the first candidate from the IBD joint research...
May 20, 2025 07:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea’s PAS-004 shows superior ETS2 inhibition vs. selumetinib, highlighting promise as a new treatment for IBD and other inflammatory diseases.
May 07, 2025 04:26 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb...